Get the Weekly Intelligence Brief — top committee picks every Sunday.
CHE · NYSE · STOCK

Chemed (CHE) Stock Analysis

Healthcare Updated September 21, 2026
$503.05
52W $365.21 – $557.00
62/100
$6.59B
25.3
0.51
AI Committee Verdict
Buy
62/100
Conviction: Contested · 50% agreement · 6 analysts
+0.9%
-0.7%
1.23:1
Contested

Is CHE Bullish or Bearish?

Bullish. Innellis AI committee rates Chemed Corp. (CHE) Buy with a composite score of 62/100 , based on 6 analysts with 50% agreement. Last updated September 21, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +13.33 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -6.67 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.

Bull & Bear Case

Bull Case
  • ROE of 29.4% shows genuine earnings power backing the valuation — Value
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
  • Low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock — Risk
Bear Case
  • Price-to-book of 6.2x prices in significant intangible value — Value
  • RSI at 29 is in oversold territory (could mean either capitulation or a bounce setup) — Technical
  • MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of September 21, 2026
Overall Committee Score
62/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 24%
of 192 Healthcare peers
Value Analyst neutral
59 / 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 29.4% shows genuine earnings power backing the valuation
− Price-to-book of 6.2x prices in significant intangible value
Growth Analyst bullish
62 / 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
Technical Analyst neutral
46 / 100 · High confidence
Mixed or range-bound price action
+ Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement
− RSI at 29 is in oversold territory (could mean either capitulation or a bounce setup)
Risk Analyst bullish
80 / 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst neutral
58 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2518.64)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 61.7 to 61.7.

Comparing 2026-09-20 to 2026-09-21 (1 day apart).

Technical Analysis

RSI (14)
28.6
Oversold
MACD Histogram
-2.762
Bearish Momentum
Trend Direction
Sideways
Weekly: Sideways
Market Structure
Mixed
Support
$499.35
Resistance
$507.64
Bollinger %B
0.15
Inside Bands
Price vs Moving Averages
EMA 9
$510.94 Below
EMA 21
$517.59 Below
EMA 50
$511.45 Below
EMA 200
$473.77 Above

Fundamental Analysis

Valuation
20
Growth
68
Profitability
70
Financial Health
55
Cash Flow
70
Valuation
P/E Ratio 25.3×
P/B Ratio 8.15×
PEG Ratio 17.13
Dividend Yield 0.50%
52W High $557.00
52W Low $365.21
Quality & Growth
ROE 2708.1%
ROA 1617.3%
Gross Margin 3044.2%
Operating Margin 1345.6%
Revenue Growth YoY
Debt / Equity 0.40
AI Fundamental Assessment
P/E ratio of 25.3 (moderate relative to a 15-40x range); Price-to-book of 8.1x; PEG ratio of 17.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 27.1%; Return on assets of 16.2%; Net margin of 10.6%; Gross margin of 30.4%; Current ratio of 0.91 (tight short-term liquidity); Debt-to-equity of 0.40; Free cash flow per share is positive (24.11); Most recent quarter beat estimates by 7.1%; 2 consecutive earnings beats; EPS growth accelerating (-12.0% -> +7.3% QoQ); Average YoY EPS growth of 41.9%; Analyst estimates falling over recent quarters
Get the Full CHE Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime